Table 1.
Patient characteristics
| G-FC (n = 21) | G-B (n = 20) | |
|---|---|---|
| Median age, y (range) | 58 (25-72) | 62 (42-80) |
| Male, n (%) | 17 (81) | 15 (75) |
| Median time from diagnosis, mo (range) | 24 (3-108) | 32 (0.4-337) |
| ECOG performance status, n (%) | ||
| 0 | 5 (24) | 3 (15) |
| 1 | 16 (76) | 17 (85) |
| Presence of B symptoms, n (%) | 11 (52) | 12 (60) |
| Rai stage III/IV, n (%) | 7 (33) | 6 (30) |
| Median lymphocyte count, 109/L (range) | 70 (5-334) | 42 (4-207) |
| Median SPD of target LN, mm2 (range) | 4 193 (215-16 080) | 3 094 (600-23 137) |
| Β2 microglobulin ≥3.5 mg/L, n (%) | 10/19 (53) | 12/16 (75) |
| Serum thymidine kinase ≥140 DU/L, n (%) | 6/7 (86) | 6/8 (75) |
| Cytogenetics, n (%) | n = 17 | n = 18 |
| 17p− | 1 (6) | 0 |
| 11q− | 4 (24) | 2 (11) |
| Trisomy 12 | 3 (18) | 5 (28) |
| 13q− | 5 (29) | 6 (33) |
| Normal karyotype | 4 (24) | 5 (28) |
| IGHV unmutated, n (%) | 9/20 (45) | 8/18 (44) |
| ZAP70 expression ≥20%, n (%) | 14/19 (74) | 11/18 (61) |
| CD38 expression ≥30%, n (%) | 8/19 (42) | 5/18 (28) |
ECOG, Eastern Cooperative Oncology Group; LN, lymph node; SPD, sum of the products of the greatest perpendicular diameters.